Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Phillips-Medisize Increases Global Manufacturing Capacity, Capabilities and Collaborations to Drive Drug Delivery, Diagnostic and MedTech Innovations

Phillips-Medisize Increases Global Manufacturing Capacity, Capabilities and Collaborations to Drive Drug Delivery, Diagnostic and MedTech Innovations

Phillips-Medisize, a Molex company and leader in the design and manufacture of drug delivery, diagnostic and MedTech devices, announces the expansion of its global manufacturing footprint, along with extended product design, development and manufacturing capabilities to streamline the delivery of game-changing products and solutions. The company’s global reach now encompasses 36 world-class facilities with scalable, end-to-end capabilities tailored to help customers bring groundbreaking products to market quickly and efficiently from anywhere in the world.

“As the preferred partner for leading global customers, we continually invest in new talent and technologies that increase the capacity and capabilities of Phillips-Medisize across the entire value chain,” said Paul Chaffin, president, Medical and Pharmaceutical Solutions, Molex. “Our expanded global reach and resources will enable us to solve complex development and manufacturing challenges while meeting escalating customer demands for more localized production, supply chain management and accelerated go-to-market strategies.”

Growing Footprint for Local Support, Global Scale

To address growing production demands from customers in continental Europe, Phillips-Medisize is building a state-of-the-art medical manufacturing facility in Katowice, Poland. Slated to open in 2022, the site will complement production sites and innovation centers in Asia, Europe, India, Mexico and North America. Phillips-Medisize also is expanding production capacity in Suzhou, China to serve both global and regional pharmaceutical and MedTech customers. Additionally, the transformation of an existing Molex production facility in Little Rock, Ark., is underway, enabling Phillips-Medisize to keep pace with ever-increasing requirements in the U.S. for high-volume, diagnostic device manufacturing.

Once these expansions are complete Phillips-Medisize will offer nearly three million square feet/280,000 square meters of country- and region-specific manufacturing space and R&D capabilities worldwide. The company also will support 600,000 square feet/55,000 square meters of Class 7 and 8 cleanrooms, which complement existing tool building sites as well as global quality and regulatory systems. In 2020, Phillips-Medisize completed a new facility in St. Croix Meadows, Wisc., with 285,000 square feet/26,000 square meters supporting production of molded components for medical diagnostic customers requiring high-volume assembly and packaging of regulated products. The facility also includes a nearly 64,000 square-foot/6,000 square-meter ISO 14644-1 Class 8 cleanroom.

Extending End-to-End Capabilities

As part of its one-stop shop of medical-device manufacturing solutions, Phillips-Medisize focuses on design for manufacturability and assembly excellence. Proven front-end innovation, human-factors engineering, and quality are integrated with regulatory adherence to reduce go-to-market risk and cost. Expanded capabilities in complex molding, drug and reagent handling, as well as final packaging and serialization, enable customers to consolidate global supply chains while optimizing go-to-market strategies.

Phillips-Medisize’s combined expertise in plastics, metals, electronics and connectivity ease the development of different solutions, including combination devices such as needle-based injection systems and wearable injection technologies. An unwavering commitment to rigorous quality management is reinforced by dedicated New Product Introduction (NPI) teams at every site. Strategic investments in talent acquisition to support Phillips-Medisize’s continued growth are expected to add at least 1,000 employees worldwide over the next couple of years.

Phillips-Medisize Brings Possibilities to Life

Phillips-Medisize, a Molex company, brings decades of innovation to leading healthcare and life science companies to develop groundbreaking solutions that help people live healthier, more productive lives. On average, the company commercializes 50 new products a year for customers, including the first-to-market FDA-registered drug-delivery device utilizing a connected health system. Molex brings decades of experience in advanced electronics, connectivity and sensor technologies to help transform medical and pharmaceutical solutions.

About Molex

Molex is a global electronics leader committed to making the world a better, more-connected place. With presence in more than 40 countries, Molex enables transformative technology innovation in the automotive, data center, industrial automation, healthcare, 5G, cloud and consumer device industries. Through trusted customer and industry relationships, unrivaled engineering expertise, and product quality and reliability, Molex realizes the infinite potential of Creating Connections for Life.

5 Compelling Reasons for Custom Developing an Appointment Scheduling App for your Healthcare Practice

5 Compelling Reasons for Custom Developing an Appointment Scheduling App for your Healthcare Practice

Developing an online appointment app or a web platform, in such a scenario, is undoubtedly the best option for your clinic. Many consumers now consider a doctor-on-demand app to be necessary for any healthcare provider, whether they are receiving care in a hospital, clinic, or private practice.

It sends a strong signal that you are on the leading edge of the medical business if you have a medication app as part of what you can offer patients. In this field, medtech advances have become essential.

So, let’s talk about why it’s important and how to make your own healthcare appointment scheduling app.

Custom apps are less expensive than you would believe, and they can provide substantial benefits over off-the-shelf solutions, particularly in the areas of business process management and digital transformation.

Here are the benefits of custom application development. 

1. Automate time-consuming activities

The custom healthcare software combines the many processes that the healthcare sector uses every day. Finance, human resources, inventory, OPD, and other basic and complicated operations may all be synchronized in one location using custom software.

2. Make co-operation easier

Since, off-the-shelf software seems to have been critical in the development of the healthcare sector, which has lately been thrown into disarray due to changes in the industry’s needs. In terms of procedures, patient care, operational areas, technology, methods, and approaches, medical institutions vary. 

Off-the-shelf software can hardly keep up with these ever-changing requirements. Custom-made healthcare software includes all the features that may help these companies not only overcome these gaps but also improve their digital automation.

3. High-Quality Patient Care

Digital transformation and innovation have the potential to revolutionize the healthcare sector by allowing for more efficient operations management and improved diagnostics at the same time.

Long lines at hospitals cause the consultation procedure to be delayed. It is one of the most common sources of discomfort for patients. This issue can be addressed to a great degree with the introduction of online scheduling software development. 

4. Safety and security

To give the best data protection to email service providers, every cloud,  chatbot, search engine, website, and application needs to be HIPAA compliant. Every day, the healthcare industry produces a tremendous amount of data and is highly customer-focused. 

When this happens, data security becomes a top priority. HIPAA compliant cloud storage of sensitive patient information assists in the protection of a patient’s information against malicious attacks or security breaches 

5. Make the most of your technology investment

EHRs/EMRs save the information of many patients in a secure HIPAA-compliant cloud environment. This lowers operational expenses and, as a result, improves the return on investment (ROI) of any healthcare institution. 

Such custom software is ideally suited for huge company development and is simple to modify. Healthcare businesses may achieve long-term sustainability by having a scalable solution developed by working with a vendor that specializes in healthcare software development. This also allows for simple operation, easy maintenance, and efficient labor procedures.

Reasons for creating an appointment scheduling app for your business

According to a recent study, 43 percent of patients prefer to schedule appointments online, and 57 percent of customers look for new healthcare providers online. Furthermore, online booking systems are said to promote patients to maintain appointments by 72 percent of patients and 60 percent of healthcare professionals.

As a result, the ability to schedule a healthcare appointment online is critical when deciding on medical services. It works like this: if you have the option of booking healthcare appointment scheduling online, you know you’ll receive the finest of contemporary treatment. 

Both patients and physicians want to feel as though they’re making the most of technology advances by automating and maximizing their time.

So, now you know what a healthcare app is, what the major choices are, and why you should start thinking about adopting it. But first, let’s look at why the basic option of booking a doctor online may have a little effect on your medical practice.

Here are the reasons for custom developing an appointment scheduling app for your healthcare practice.

More accessible healthcare

A medical appointment scheduling app may also assist patients and physicians feel more at ease in situations that are quickly becoming more frequent, such as the introduction of medical video conferencing software. 

Patients who are unable to move, for example, may consult with their doctor from home if they have the app and a smartphone or tablet.

Patients may also benefit from the incorporation of a bespoke support platform. They generally enjoy being able to pay their bills online rather than having to contact a doctor’s office with their credit card information or mail a check. 

It translates to a better return on investment (ROI) for the hospital, clinic, or whatever other medical institution is involved.

Saving money on the Doctor-on-Demand Platform

When contemplating how a healthcare appointment scheduling app might assist you, cost-cutting may be the first thing that comes to mind. This is true for patients as well as medical institutions.

The typical patient visit earns $100-$150 for primary care practitioners. Each week, if two of the ten-time slots remain vacant, the loss is $1,000. 

Revenue becomes uncertain when combined with a 23-34 percent no-show rate, according to the American Journal of Medicine. As a result, many scheduled consultations are canceled due to the patient and are not replaced by another appointment.

When clinics and hospitals have online scheduling software in place, they may save money by using a doctor booking app. This allows them to better manage consultations. They can keep track of cancellations so that physicians have a greater chance to see one of their other clients if someone cancels a last-minute appointment. 

As a result, this kind of medical software may help doctors manage their workload and prevent wasted time slots, which can save money.

Furthermore, 34.3 percent of appointments made via online platforms were made while the business was closed when no one would have been available to take a call.

Offline & Online Medical Practices Expanded

Healthcare appointment scheduling app development is common, which implies that medical practices have the time and resources to grow and flourish. This kind of software may allow physicians to see more patients and gain more experience. 

According to the Deloitte study, a mobile doctor booking system enables two additional patients to be seen each day. As a consequence, the provider’s revenues rise as job efficiency improves and physicians’ experience grows.

Final thoughts

Custom application development has many advantages. And, as internal systems get more sophisticated and businesses become more specialized, customization is becoming the rule rather than the exception.

However, “custom” does not always imply “expensive.” You can get a lot of customization advantages without spending a lot of money if you use current software and customize it using bolt-on solutions.

It’s difficult to overlook bespoke application development when it comes to getting the most out of your software.

Trinity Health Invests in Xealth to Accelerate Digital Health

German hospitals to get €3 billion funding boost for digitalisation

Xealth, the leader in enabling digital health at scale, today announced that Trinity Health, one of the nation’s largest Catholic health care systems, has invested in the company. Trinity is one of 15 health system investors for the company, bringing the total Series B funding to $25 million. This support demonstrates continued provider consensus in adopting digital health in a way that best engages both clinicians and patients.

“As we have seen during COVID-19, digital health can enhance care delivery and improve engagement between our clinicians, patients and the communities we serve. Xealth has impressive experience connecting health solutions across a range of services, including maternity, diabetes, heart disease, and many others,” said Marcus Shipley, chief innovation and information officer for Trinity Health. “We value Xealth’s digital platform with pre-built integrations that span across digital content, apps, device monitoring as well as non-clinical services.”

Digital therapeutics, mobile apps, and remote patient monitoring help fill a necessary role in extending care options for patients. In September, Xealth announced Advocate Aurora Enterprises, Banner Health, ChristianaCare, Cone Health, Memorial Hermann, Nebraska Medicine, Novant Health and Stanford Health Care joining existing health system investors Atrium Health, Cleveland Clinic, Froedtert & MCW Health Network, MemorialCare Innovation Fund, Providence and UPMC. Collectively, these 15 health systems represent millions of patients and more than 100,000 physicians across 34 states.

“Care delivery is evolving with digital health offering an opportunity for health systems to address a variety of goals, including expanding services, higher engagement and addressing clinician resources,” said Mike McSherry, CEO and co-founder of Xealth. “The incredible support that we have received from leading health systems, including Trinity Health, demonstrates the value in Xealth’s approach to rolling out digital health that empowers both providers and patients, creating a personalized care experience that deepens the connection between patients and care teams.”

Xealth’s digital health platform serves a critical role in bringing digital health into clinicians’ workflows, an essential element for program success. It delivers centralized integration, prescribing, monitoring and governance for digital health tools from current clinician workflows, demonstrating a 50-80 percent reduction in integration and deployment costs, and substantial patient engagement with digital assets. Successful programs have been initiated around maternity, diabetes, behavioral health, heart disease, kidney disease, advance directives, infectious disease, surgery preparation and many other areas of care.

Hospitals and providers can further leverage intelligent automation and gain insight into how each tool is performing with patients. Patients can be enrolled in beneficial programs and share information directly with care providers through the EHR.

Spun out from Providence in 2017, Xealth has backing from 15 health systems and full integrations with the largest EHR vendors. Additional investors include Cerner, LRV Health, Threshold Ventures, McKesson Ventures, Novartis, Philips, and ResMed.

Philips introduces next-generation Digital Pathology Suite IntelliSite to enhance diagnostic confidence and streamline pathology lab workflows

Philips introduces next-generation Digital Pathology Suite IntelliSite to enhance diagnostic confidence and streamline pathology lab workflows

Royal Philips, a global leader in health technology, announced the launch of its next-generation digital pathology solution, moving digital pathology into the heart of enterprise-wide healthcare informatics. Philips Digital Pathology Suite – IntelliSite – features a comprehensive, scalable suite of software tools and capabilities designed to help streamline workflows, enhance diagnostic confidence, facilitate team collaboration, integrate artificial intelligence (AI) and increase the efficiency of pathology labs.

Philips Digital Pathology Suite offers a range of solutions designed for different use cases with an affordable cost of ownership. From low-volume ‘spoke’ labs or small independent labs, where small batches of slides are continually processed and scanned, to medium and large labs operating high-volume batch processing workflows. The hardware is also pre-equipped for multi-layer slide scanning. Images are captured in a centralized informatics platform that has been optimized around pathologists’ workflows, integrating with leading third-party AI tools and algorithms with the aim to further reduce laboratory costs and enhance diagnostic capabilities.

“Integrated diagnostic capabilities are a cornerstone to a precise diagnosis and personalized care pathway selection for oncology patients and only when data and specialties work together in harmony can the ultimate promise of care be realized,” said Louis Culot, General Manager Oncology Informatics at Philips. “That’s why bringing together multiple pieces of the healthcare continuum – like radiology, pathology, and genomics – is the key to a new paradigm of diagnostic precision. By providing pathologists the interoperability and connectivity to share high-quality images and diagnostic insights across networks, Philips Digital Pathology Suite positions them as key stakeholders in the data-driven healthcare systems of the future.”

Digital Pathology Suite includes a range of three pathology slide scanners, as well as Pathology Workspace – Image Management System – a comprehensive set of software tools and capabilities that encompass every stage of the digital pathology process, including an advanced image management system, bidirectional interoperability into laboratory information systems, and a case viewer that facilitates multidisciplinary case reviews and care pathway selection. Diagnostic confidence is enhanced by superb image quality and advanced algorithms, such as automatic tissue shape detection and non-rectangular optimization of regions of interest. Vendor-agnostic data interoperability also allows the easy sharing of patient-centric histology data across enterprises and between sites.

“MEDIPATH is focused on accelerating the path of augmented pathology by slide digitalization on all our technical platforms. We are very excited to leverage the new Philips Digital Pathology Suite, including the Pathology Scanner SG300 and Pathology Workspace with de-identification tools, for each of our sites,” said Stephane Rossat, Director for innovation, science and project management at MEDIPATH, a French Pathology group with a network of 11 technical labs. “Following the first days of installation, the solution is already proving easy to use, with images generated more quickly, while the quality and sharpness of the images produced is experienced to be superior. The Philips Digital Pathology Suite is the solution that our organization needs to expand our digital pathology capabilities and activate our transformation.”

Integrated intelligence and automation across smart diagnostic systems

Precision medicine has increased the volume and complexity of workloads, with pathology labs worldwide facing a shortage of skilled staff. Within the diagnosis and staging of cancer, pathology information is combined with data from multiple disciplines, including radiology, pathology and genomics, to deliver the diagnostic precision required for highly personalized care. There is an urgent need for solutions that combine operational efficiency, team-working, expertise sharing, and enterprise-wide informatics to make the most of a pathology lab’s human resources.

Through breakthrough innovations and partnerships, Philips integrates intelligence and automation into its Precision Diagnosis portfolio, including smart diagnostic systems, integrated workflow solutions with the aim to transform departmental operations, advanced informatics that enhance diagnostic confidence, and care pathway solutions that allow medical professionals to tailor treatment to individual patients. By developing and integrating AI-enabled applications, the company aims to enhance the ability to turn data into actionable insights and drive the right care in the right sequence at the right time.

About Royal Philips

Royal Philips  is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries.

Botco.ai and VerifyTreatment Partner to Enable Addiction and Rehabilitation Centers to Instantly Verify Insurance Via AI Chat

Botco.ai Launches BotcoLive, Combining AI Chat and Live Agent Support to Maximize Marketing Contact Resolution

Botco.ai, the leading HIPAA-compliant conversational marketing platform, announced a partnership with VerifyTreatment, a cloud-based platform that provides instant insurance verification for the behavioral health industry, that enables healthcare centers to instantly verify their prospects’ insurance through Botco.ai’s AI-based chat platform. The industry-first solution provides instant and accurate answers to consumers’ questions about insurance coverage while enabling healthcare centers to engage with interested applicants and convert more patients. Some of the nation’s largest Addiction and Rehab centers are already testing the joint solution.

“Addiction centers report that before a new patient starts at a treatment center across the country, one of the first questions they have is whether the treatment is covered by their insurance,” said Jacob Molina, Product Manager at Botco.ai. “It can normally take several hours to get a response from the insurance provider, which is a waste of time and a serious pain for the patient. Using Botco.ai and VerifyTreatment, addiction and rehab centers can provide immediate answers to nearly all insurance questions directly through the chatbot on their website or Facebook page. Not only does this ease the administrative burden of having to research insurance coverage, but it puts the prospective patient’s mind at ease right away and helps the provider convert more prospects into patients.”

Botco.ai’s conversational marketing platform enables healthcare providers to provide fast and accurate answers to their prospects’ questions via an easy, conversational experience that complies with all HIPAA policies. Through its partnership with VerifyTreatment, which provides single sign-on access to thousands of top insurance plans, Botco.ai now enables healthcare providers to immediately answer prospects’ insurance questions, such as whether or not they are covered, which services are covered, what costs are associated with services, and more. By providing immediate answers to insurance questions instead of waiting to hear back from the insurance companies, healthcare providers can dramatically reduce drop-off and increase their patient conversion rates.

“When patients are researching healthcare facilities, they’ll often rule out any facility that isn’t able to verify insurance coverage in a timely and efficient manner,” said Jon Wagner, CEO of VerifyTreatment. “Our solution was built so that healthcare facilities don’t have to risk losing a patient by waiting hours on verification and they can be the first center to say ‘yes’ to insurance questions. By partnering with Botco.ai on verification through chatbots, it’s now easier than ever for patients to get the answers they need, right when they need them.”

“We are on a mission to help people throughout the world get critical answers to their healthcare questions without having to wait, and our partnership with VerifyTreatment is a big step in that direction,” said Rebecca Clyde, CEO of Botco.ai. “We feel that this solution is going to help alleviate a lot of stress for countless numbers of patients and help them get the treatment they need that much faster, while helping healthcare providers operate more efficiently and effectively. It’s exciting to see how quickly AI chat is revolutionizing the healthcare space, and we are very proud to play a role towards that progress.”

Botco.ai and VerifyTreatment will co-host a webinar on “Behavioral Health Marketing: How to Convert Live Chats Into Patients Using AI-powered Chatbots and Real-time Insurance Verification” on November 2nd at 11:00 am PDT. To register, visit www.botco.ai.

About Botco.ai
Botco.ai is a HIPPA-compliant, AI-powered marketing chat solution that can be implemented at scale to improve engagement rates. Today, the company offers industry-leading authoring, webchat, and AI machine-learning capabilities to quickly and effectively convert more customers in healthcare, wellness, addiction, behavioral health, physical therapy and senior living centers. Botco.ai’s new Integrated Analytics Dashboard provides a comprehensive view of chat campaigns across multiple messaging channels such as web and Facebook Messenger. The API-based interface can be used to transfer leads, transcripts, and data into enterprise sales and marketing automation products like Salesforce, Hubspot, Adobe Marketing Cloud, Zoho as well as leading EHR and scheduling systems. Botco.ai is the recipient of the Arizona Innovation Challenge “Most Outstanding Startup” award and a graduate of Alchemist Accelerator Class XXV, the #1 accelerator for enterprise startups.

About VerifyTreatment
VerifyTreatment is a cloud-based platform that provides instant insurance verification for the behavioral health industry. The platform makes the admissions process faster and easier to avoid lost clients. The company partners with and is trusted by thousands of healthcare centers, treatment facilities and billing companies in over 46 states, nationwide, to admit more patients and increase revenue. Its customers have verified over 2 million policies, helping close the gap between insurance submission and patient admission. It was founded in 2016 and is based in Delray Beach, Florida, USA.

Roche announces collaboration with Ibex Medical Analytics to develop AI based digital pathology applications for improved patient care

Roche announced that it has entered an agreement with Ibex Medical Analytics, a global leader in artificial intelligence (AI)-based cancer diagnostics. Under the agreement, the companies will jointly develop an embedded image analysis workflow for pathologists to seamlessly access Ibex’s AI algorithms, insights, and decision support tools using NAVIFY Digital Pathology, the cloud version of Roche’s uPath enterprise software. Collaborations with leading AI companies like Ibex are made possible through Roche’s Digital Pathology Open Environment, which allows pathologists to securely access third-party AI-powered technology alongside Roche’s growing menu of AI-based image analysis tools.

Ibex’s Galen™ platform was recently granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) and is CE marked in Europe for breast and prostate cancer detection in multiple workflows. Through this alliance, customers using Roche Digital Pathology will gain access to Ibex’s innovative tools, such as algorithms that analyse prostate and breast biopsies, in addition to the AI tools already provided by Roche.

“With the addition of Ibex’s clinical-grade image analysis tools to our NAVIFY Digital Pathology menu, we can aid pathologists and providers in delivering value-based patient care by increasing their efficiency and accuracy for higher quality cancer diagnosis,” said Jill German, Head of Roche Diagnostics Pathology Customer Area.

The clinical-grade AI algorithms and digital workflows included in this expanded menu of tools will enable pathologists to provide accurate, efficient and timely diagnoses for their patients and support them in the detection and grading of cancer, identification of important non-cancerous features, case reporting and more.

“Digital pathology provides the capability to introduce new, innovative ways for laboratories to improve quality and efficiency of cancer diagnosis. Together with Roche, we look forward to transforming pathology by delivering powerful AI-based tools to the fingertips of pathologists,” said Joseph Mossel, CEO and Co-founder of Ibex Medical Analytics.

About Roche Digital Pathology

As the leading provider of pathology lab solutions, Roche is delivering the end-to-end digital pathology solution from tissue staining to producing high-quality digital images that can be reliably assessed using automated clinical image analysis algorithms. We minimise variables that can impact analysis, and it is this end-to-end development that produces the quality results healthcare providers and researchers can depend on. With the acceleration of immunotherapy and the development of more complex assays, Roche is moving these traditionally research-oriented tools into routine clinical practice and is committed to investing in and shaping the future of pathology.

Roche offers two deployment options for its uPath software: an on-premise solution and a cloud solution, marketed as NAVIFY Digital Pathology. The VENTANA DP 200 slide scanner and Roche uPath enterprise software are CE-IVD marked for in-vitro diagnostic use and are available in the U.S. for research use only (RUO). Image analysis algorithms developed by third-party entities and their utilisation are the responsibility of the third party provider.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Modern Healthcare Launches Digital Health Business & Technology To Serve The Entire Digital Health Ecosystem

Verizon Business launches BlueJeans Telehealth for better connected health

Modern Healthcare, a Crain Communications brand, is pleased to announce the launch of Digital Health Business & Technology, a digital media brand that covers the latest news, data and insights on all aspects of digital healthcare technologies, from hardware, software products and services to finance, investment and mergers and acquisitions activity.

The new digital brand leverages the editorial expertise of Modern Healthcare, an industry-leading provider of healthcare business news for more than 45 years, as well as 10 years of global digital health deal information and analysis acquired from Mercom Capital’s Digital Health Business in June 2021.

The resulting product portfolio will include:

  • The Digital Health Business and Technology website (DigitalHealthBusinessandTechnology.com), featuring news coverage, a research and data center and quarterly M&A reports
  • The Digital Health Deal and Digital Health Intel weekly e-newsletters
  • A Digital Health Alert for breaking industry news

For a limited time, healthcare executives in senior leadership roles in operations, financial and clinical management, information technology and related areas; entrepreneurs and senior leaders within digital health solution provider companies; investment firms, private and institutional investors (commercial banks, mutual funds, etc.), venture capitalists; private equity firms and angel investors, are invited to register for trial access to online content and e-newsletters from Digital Health Business & Technology.

Digital Health Business & Technology offerings will serve the needs of the entire digital health ecosystem, enabling healthcare executives, entrepreneurs, business leaders and investors to determine how best to leverage digital health solutions for improved outcomes, accelerated innovation and greater business growth,” said Fawn Lopez, publisher of Modern Healthcare.

“Our digital health portfolio will serve the information needs of healthcare executives who are seeking to understand the strategic business value of the latest digital health technology solutions to their operations, along with technology professionals at provider and clinical organizations who evaluate and determine which technology solutions are the right fit for their digital health strategies, and investors who track deals, IPOs and M&A activity to identify trends for future investment in digital health companies,” said Jon Morton, general manager of Digital Health Business & Technology.

According to McKinsey & Company, in 2019, digital health represented a global market worth approximately $350 billion. All digital health value pools are expected to grow by at least 8% annually through 2024, leading to an estimated market size of at least $600 billion.

https://www.asianhhm.com/news/modern-healthcare-launches-digital-health-business-technology

Early Diagnosis with Triple Assessment is a Cure to Breast Cancer: Says Expert

Cancer has been a menace to society since time immemorial, with people suffering severely all over the world at the hands of the disease. A study conducted by the National Cancer Registry Programme revealed that the projected number of cancer patients in India was 1,392,179 for the year 2020. Of these, 57% of cases diagnosed at the locally advanced stage were for breast cancer.

This ‘Breast Cancer Awareness Day,’ HEAL Foundation organised a Breast Cancer Awareness Dialogue in association with HEAL Health to discuss that breast cancer is curable if diagnosed early. This was the 22nd Episode of the HEAL-Thy Samvaad series.

While speaking at the ‘Breast Cancer Awareness Dialogue’ – the 22nd Episode of HEAL-Thy Samvaad, Dr P. Raghu Ram, Director & Consultant, Surgeon-KIMS-USHALAKSHMI Centre for Breast Diseases, said, “Early diagnosis plays a pivotal role in the cure of breast cancer. However, when a patient visits a doctor, and before the diagnosis is made, the patient should be in a place where she should have what is called ‘triple assessment’ – this includes taking the history & examining the patient (which is the first component; the second component is a combination of having a mammogram (an x-ray of the breast) and an ultrasound scan, and the third component is under ultrasound guidance, a core needle biopsy. When this triple assessment gets done, the first thing that must happen is to provide adequate counselling to the patient. By counselling, we calm the patient, since cancer not only affects the body, it also affects the mind.”

At the 22nd Episode of HEAL-Thy Samvaad, sharing her experiences with her battle with Breast cancer, the breast cancer conqueror – Ms Shalini Nayar said, “Things like shock, ‘why me’, ‘what did I do’, are very natural. I was the first member of the family to get cancer, so it was a whole jumble of emotions like regret and fear. As Dr Raghu Ram has said that the doctor needs to counsel the patient, it took me 2-3 days to come to terms with reality, after which I decided that it is what it is and I need to put things aside and fight this battle. With the medical expertise of Dr Raghu Ram and his entire team, and with the support of my family, I decided to concur with this battle and emerge victoriously. My message to the breast cancer patients is — get your timely test done; don’t neglect it; don’t put a gap of timing as I started the treatment during COVID without waiting, be happy and don’t get down.    

Moderating the 22nd Episode of HEAL-Thy Samvaad, Dr Aloke Mullick, Group CEO, OMNI Hospitals said, “Usually the breast cancer cases are diagnosed at the advanced stage in India where the cure seems difficult. Thus, it is imperative to diagnose breast cancer at an early stage because it paves the way to cure the disease. However, there is a lack of awareness about the disease in the masses which is essentially required to be inculcated. The number of breast cancer cases is seen to be increasing across the geographies, which can be prevented by spreading awareness about early diagnosis.”

Elaborating on the key demography and rates of incidence associated with the spread of breast cancer at the 22nd Episode of HEAL-Thy Samvaad, Dr Senthil Rajappa, Medical Oncologist, Basavatakaram Indo-American Cancer Hospital and Research Institute, said, “The incidence of breast cancer in India is somewhere around 27-30 per hundred thousand per year. If you compare this to the western world, North America for example, the incidence of breast cancer is 130 per hundred thousand per year. In terms of geography, for unclear reasons, the Hyderabad Cancer Registry has revealed that 48 per hundred thousand in Hyderabad is the highest geographical rate in the country. Breast cancer is a lifestyle disease, and population-based cancer registries are not as robust as they are in the western world which is why the reported numbers are less.”

Dr T Subramanyeshwar Rao, Surgical Oncologist, Basavatakaram Indo-American Cancer Hospital & Research Institute said, “The list of approved surgeries keeps on changing, like in the west. For various reasons, only limited breast conservation surgeries used to happen earlier. However, science had to catch up – once the surgeon and the patient were convinced, the community, educated by the media, also played a major role. We also noted that those patients whose family members have survived breast cancer have a higher chance of undergoing mastectomies. Therefore, we need to diagnose and treat it early.”

Brooks Automation and Cleveland Clinic Celebrate Opening of Biobanking Facility

Brooks Automation and Cleveland Clinic Celebrate Opening of Biobanking Facility

Brooks Automation, Inc. and Cleveland Clinic have opened a new 22,000-square-foot biospecimen sample management and repository facility on Cleveland Clinic’s main campus. The two-story biorepository is managed by Azenta Life Sciences, Brooks’ recently re-branded life sciences division, and includes ultra-cold and cryogenic storage for researchers at Cleveland Clinic and other institutions. The new facility increases biobanking capacity at Cleveland Clinic and will help accelerate translational research.

“Biobanking is essential for the evolution of personalized medicine for conditions, such as heart disease, cancer and epilepsy,” said Serpil Erzurum, M.D., Cleveland Clinic’s Chief Research and Academic Officer. “This technologically advanced biorepository will enable research that allows us the knowledge to provide the best care for all people as part of Cleveland Clinic’s mission: caring for life, researching for health, educating those who serve.”

Azenta Life Sciences operates biorepository facilities across the United States and around the world. All sample and material management facilities utilize one global, interconnected platform for complete sample visibility and maximum control. The new biorepository allows researchers at Cleveland Clinic and others to more quickly advance laboratory discoveries into new treatments for patients.

“The storage of biological samples safely and efficiently is an integral part of the research process allowing researchers to focus on breakthroughs in areas, such as personalized medicine and therapeutic development,” added Sarah Eckenrode, Ph.D., Vice President, Sample & Repository Solutions, Azenta Life Sciences. “The onsite sample biorepository standardizes sample collection, processing and storage protocols to increase scalability and efficiencies for Cleveland Clinic’s high-value collections of biological material.”

“Through this first-of its-kind strategic relationship between Cleveland Clinic and Azenta Life Sciences, we are bringing state-of-the-art sample management capabilities directly to Cleveland-area researchers,” explained Linda De Jesus, Senior Vice President and Chief Commercial Officer, Azenta Life Sciences. “The onsite biorepository will strengthen the collaboration between our institutions and enable Cleveland Clinic researchers to do what they do best, improve patient care and save lives.”

In addition to the biorepository, the building will also serve as a community resource to improve awareness of ongoing research and career opportunities in the medical and scientific field. This includes a community room – a Research Access Center – where members of the local community can learn more about medical research. The community room also will serve as an educational resource for local students to meet and interact with healthcare professionals to learn about careers in medicine, the health professions and health sciences.

About Brooks Automation
Brooks operates two global, market-leading businesses, Life Sciences and Semiconductor Solutions, each with its own distinct area of focus and expertise. The Life Sciences business, to be operated under the new Azenta brand, provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry’s top pharmaceutical, biotech, academic and healthcare institutions globally. On September 20, 2021, the Company announced the pending sale to Thomas H. Lee Partners of its Semiconductor Solutions Group business, which provides industry-leading precision vacuum robotics, integrated automation systems and contamination control solutions to the world’s leading semiconductor chip makers and equipment manufacturers as well as collaborative robotics and automation capabilities for multi-market applications. Brooks is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia.

About Cleveland Clinic
Cleveland Clinic – now in its centennial year – is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. Among Cleveland Clinic’s 70,800 employees worldwide are more than 4,660 salaried physicians and researchers, and 18,500 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,500-bed health system that includes a 173-acre main campus near downtown Cleveland, 19 hospitals, more than 220 outpatient facilities, and locations in southeast Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2020, there were 8.7 million total outpatient visits, 273,000 hospital admissions and observations, and 217,000 surgical cases throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 185 countries. Visit us at clevelandclinic.org. Follow us at twitter.com/ClevelandClinic.

New Study Reveals 20% of Healthcare Organization Executives Fully Trust Their Data

Time to align healthcare data standards with the reality of care

Sage Growth Partners, a research firm that accelerates commercial success for growth-minded health organizations, released recent findings from its first Market Report on Data Analytics. Commissioned by InterSystems, an innovative data technology provider dedicated to helping customers solve the most critical information challenges, the study surveyed 100 healthcare organization executives to identify the most common data obstacles and how to address them. According to the research, only 20 percent of those surveyed fully trust the data they rely on to make decisions. 

Despite the progress made in healthcare IT over the past decade, hospitals and health systems continue to struggle with the collection, normalization, analysis, and application of data to make timely clinical and business decisions. The report revealed that 85 percent of organizations saw data analytics priorities as fundamental to achieving broader strategic objectives. Furthermore, more than half of respondents stated that poor data quality has serious consequences and can lead to ineffective or slow decision making (53%) and the inability to identify gaps in care (50%). 

“Sage’s survey findings are consistent with what we hear from health systems,” said Fred Azar, Analytics Executive at InterSystems, “Executives acknowledge that poor data impedes enterprise decision making and their ability to identify gaps in care, and that data integration and interoperability is a significant barrier to their analytics strategy.

Additional key findings include:

  • Data integration and interoperability is by far the biggest barrier to achieving strategic data analytics priorities in the coming year according to 51% of respondents 
  • High-quality data is a top strategic priority, yet most (80%) don’t fully trust their data.
  • Creating and sharing high-quality data across their organization is the top short-term and long-term strategic priority (80% within the next 12 months, 84% within the next 36 months). 
  • About half of respondents say data and data management challenges impact their data and analytics teams by creating long delays, difficulty scaling and democratizing data, and limited time to analyze the data.

“There is an enormous amount of health data in today’s digital world, which is growing daily because of the increasing use of wearables and health apps that collect and share health data,” said Stephanie Kovalick, Chief Strategy Officer at Sage Growth Partners. “The potential that exists if this information can be leveraged in managing people’s health is also enormous. However, all this information quickly loses its value if there isn’t a way to appropriately apply the data. As reflected in our study, without reliable, clean, and actionable data, organizations are left with an exorbitant amount of data wasted that otherwise could be used to inform critical, life-saving clinical decisions.” 

InterSystems will share additional insights into the criticality of clean, actionable data to enable leaders to achieve their strategic priorities at this year’s InterSystems Virtual Summit, October 26 – October 28, 2021. Download the report and register today to learn more: https://www.intersystems.com/virtual-summit-2021-notifications/ 

About Sage Growth Partners 

Sage Growth Partners  accelerates commercial success for B2B, B2B2C, and B2C healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. Founded in 2005, Sage Growth Partners is located in Baltimore, MD, and serves clients such as Pyx Health, the National Minority Health Association, Philips Healthcare, U.S. Renal Care, Quest Diagnostics, Livongo, Olive, and iN2L.

1...391392393...1,127Page 392 of 1,127

About us

Hospital & healthcare Management is a leading B2B arena designed for the healthcare sector, it allow members to reach both ends of the healthcare facility procurement chain. . . Read More

Subscribe us

System

Resources

Archive Links

Subscribe

Copyright © 2008 - 2026 Hospital & Healthcare Management. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »